Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...

Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...

Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

Signaturefd LLC raised its position in shares of Genmab A/S by 163.2% in the 4th quarter. Signaturefd LLC now owns 20,790 shares of the company’s stock valued at $434,000 after purchasing an ...

Genmab has also granted restricted stock units and warrants to its employees, further promoting workforce retention and alignment with shareholder interests. In terms of financial performance ...

Genmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration ...

However, the analyst also pointed out that the overall visibility into Genmab's operations is somewhat obscured, with limited news flow beyond the Darzalex updates. This uncertainty has tempered BNP ...